Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • International phase III trial: Balixafortide (a CXCR4 antagonist) + eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast cancer (FORTRESS)
    Meeting Abstract

    Kaufman, P. A.; Martin, M.; Mayer, I.; Vahdat, L. T.; Pernas Simon, S.; Schmid, P.; McArthur, H. L.; Dent, R.; Rugo, H. S.; Barrios, C.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
    Meeting Abstract

    John, T.; Chiu, C. H.; Cho, B. C.; Fakih, M.; Farago, A. F.; Demetri, G. D.; Goto, K.; Doebele, R. C.; Siena, S.; Drilon, A.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study
    Meeting Abstract

    AndreĢ, T.; Amonkar, M.; Norquist, J.; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C. J.; Smith, D.; Garcia-Carbonero, R.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2-positive (HER2+) advanced breast cancer (ABC)
    Meeting Abstract

    Hurvitz, S. A.; Chia, S. K. L.; Ciruelos, E. M.; Hu, X.; Im, S. A.; Janni, W.; Jerusalem, G.; Lacouture, M.; O'Regan, R.; Rugo, H. S.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer
    Meeting Abstract

    Hurvitz, S. A.; Vahdat, L. T.; Harbeck, N.; Wolff, A. C.; Tolaney, S. M.; Loi, S.; Masuda, N.; O'Shaughnessy, J.; Dong, C.; Walker, L.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) + fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2- LA/MBC)
    Meeting Abstract

    Turner, N.; Jhaveri, K.; Kalinsky, K.; Loibl, S.; Loi, S.; Im, S. A.; Saura, C.; Schmid, P.; Schutzman, J. L.; Stout, T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies
    Meeting Abstract

    Powell, C. A.; Camidge, D. R.; Modi, S.; Qin, A.; Taitt, C.; Lee, C.; Hackshaw, M. D.; Singh, J.; Iwata, H.
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2- BC)
    Meeting Abstract

    Gambardella, V.; Cervantes, A.; Bedard, P. L.; Hamilton, E. P.; Italiano, A.; Jhaveri, K.; Juric, D.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation
    Meeting Abstract

    Sharma, P.; Farooki, A.; Fasching, P. A.; Loi, S.; Peterson, K.; Prat, A.; Tripathy, D.; Xu, B.; Yardley, D. A.; Mills, D.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2- breast cancer (CAPItello-291)
    Meeting Abstract

    Turner, N.; Howell, S.; Jhaveri, K.; Gomez, H.; Toi, M.; Hu, X.; Loibl, S.; Rugo, H. S.; Ni, P.; De Bruin, E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save